ONO-1301

Research use only, not for human use.

A stable, orally active, non-prostanoid prostacyclin I2 (PGI2) mimetic and prostacyclin agonist with inhibitory activity against thromboxane A2 synthase.

A stable, orally active, non-prostanoid prostacyclin I2 (PGI2) mimetic and prostacyclin agonist with inhibitory activity against thromboxane A2 synthase; suppresses the elevation of protein excretion into urine in rats, attenuates the development of bleomycin-induced pulmonary fibrosis and improves survival in bleomycin mice.Thrombosis Discontinued.

ONO 1301 (ONO-AP 500-02) inhibits collagen-induced aggregation in a concentration-dependent manner, with an IC50 value of 460 nM.ONO-1301 (0-1000 nM) significantly increases alkaline phosphatase (ALP) activity in the primary osteoblasts and ST2 cells.

ONO-1301 (6 mg/kg; p.o.; /daily for 4 weeks) improves the hemodynamic status of rats with dilated cardiomyopathy after experimental autoimmune myocarditis. Animal Model:Eight-week-old male Lewis rats (rat model of myosin-induced experimental autoimmune myocarditis)Dosage:6 mg/kg Administration:Orally; /daily for 4 weeks Result:Hemodynamic parameters and plasma brain natriuretic peptide (BNP) level were significantly improved.

ONO 1301 | ONO1301

GPCR/G Protein

Prostaglandin Receptor

Prostaglandin Receptor

Cardiovascular Disease

Thrombosis

176391-41-6

428.488

C26H24N2O4

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (116.69 mM)

O=C(O)COC1=C2CCC(C)=C(CCO/N=C(C3=CC=CC=C3)\C4=CC=CN=C4)C2=CC=C1

[7,8-dihydro-5-[(E)-[[a-(3-pyridyl)benzylidene]-aminooxy]ethyl]-1 -naphtyloxy]acetic acid

(-20℃)

With Ice Pack

≥ 2 years